Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05613985
Other study ID # MOLT-2019-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 14, 2021
Est. completion date December 31, 2024

Study information

Verified date November 2023
Source L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
Contact Ilaria Corti
Phone 0557361193
Email i.corti@moltenifarma.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this randomised, open-label, multicentre clinical trial is to evaluate the superiority of the treatment which foresees the addition of the system VULNOFAST® plus / VULNOLIGHT® to the Usual Care, versus the treatment with Usual Care alone, for the healing of chronic diabetic foot ulcer. VULNOFAST® plus is a sterile solution used in combination with a red light source VULNOLIGHT®. Usual Care is defined as procedures to apply to the foot ulcer, carried out in the order in which they are listed in the protocol.


Description:

This study evaluates the superiority of the treatment which foresees the addition of the system VULNOFAST® plus / VULNOLIGHT® to the Usual Care, versus the treatment with Usual Care alone, for the healing of chronic diabetic foot ulcer. Eligible patients are randomised in a 1:1 ratio to receive Usual Care and the system VULNOFAST® plus / VULNOLIGHT®, or Usual Care alone according the following scheme: - Arm A: Usual Care alone: 2 times a week (4 treatment weeks, 8 treatments). - Arm B: system VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care: both treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®). The Treatment period will be followed by a Follow up period: the study will last up to 57 days for each patient, including the screening period. Thirteen study visits are planned starting from the screening and including Treatment and Follow up periods. All patients enrolled in this study: - are administered with amoxicillin and clavulanic acid treatment (as background antibiotic therapy) from Visit 1 until receipt of the antibiogram. Upon receipt of the antibiogram, the Investigator decides whether or not to continue the background therapy or to treat the patient with a different antibiotic treatment, according the clinical practice in the site. - use an appropriate off-loading system from Visit 1 to Visit 12 The primary objective is to assess clinical improvement after 2 weeks of study treatment by evaluation of the following primary endpoint: - proportion of patients who had total bacterial load ≤ 1000 CFU/ml at Visit 5 (Visit 5 is the first visit of 3rd week of treatment), measured by punch biopsy. The key secondary objective is also to assess clinical improvement after 4 weeks of study treatment reflected by the key secondary endpoint: - proportion of patients who had a reduction of the target ulcer area ≥ 40% from the baseline (Visit 1) to the first follow-up visit (Visit 9) after 4 weeks of study treatment, assessed by MolecuLight i:X medical device. Further secondary objectives are evaluated in the study, and a pharmacoeconomic analysis is foreseen.


Recruitment information / eligibility

Status Recruiting
Enrollment 146
Est. completion date December 31, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Main Inclusion Criteria: - Able and willing to give voluntary written informed consent. The ICF, must be signed before any study-related procedures and/or assessments are performed. - Outpatients or inpatients (male and female) of any ethnic origin, aged 18 years or over, diagnosed with type 1 or type 2 diabetes mellitus. - Glycaemic control confirmed by a glycated haemoglobin (HbA1c) levels =10% (86 mmol/mol), evaluated in the 3 months before enrolment or at Visit 1. - Fasting plasma glucose (FPG) less than 300 mg/dl. - A chronic diabetic foot ulcer (DFU) below the malleolus, with an area = 2 and = 40 cm2 and with a maximum diameter/length = 10 cm measured by MolecuLight i:X medical device [note: chronic wound is defined as a wound that, after the normal clinical practice, does not start healing within 4 weeks or does not heal within 8 weeks]. - A diabetic foot wound with a depth equal or higher to grade 2 according to the category "Depth/tissue loss" of PEDIS, but not involving bone, diagnosed by clinical examination. - Presence of infected foot ulcer of grade 2 according to the category "Infection" of PEDIS, diagnosed by clinical examination. - Able to take oral medications. - Patients must be willing and able to comply with the protocol and study procedures. Main Exclusion Criteria: - Patients unable to give written informed consent. - Females who are pregnant or lactating. - Females who are of child bearing potential and not taking adequate contraceptive precautions are excluded from the trial. Females of child bearing potential taking acceptable contraceptive precautions can be included. - Participation in any other clinical trial or currently receiving any other investigational product(s) within 30 days prior to Visit 1. - Ankle brachial systolic blood pressure index < 0.5 (Winsor Index) in the infected limb. - Ulcer probe to bone positive. - Any surgery planned during the study period (from ICF signature to last planned follow-up visit). - Clinical diagnosis of peripheral vascular disease (PVD) requiring percutaneous or surgical revascularization. - Transcutaneous oximetry (TcPo2) measurement < 30 mmHg. - Use of any antibiotics (local or systemic) within 48h before Visit 1. - Patient for whom punch biopsy is contraindicated. - Patients that cannot take amoxicillin and clavulanic acid (background antibiotic therapy) at the dosage stated in the protocol and according to the current Summary of Product Characteristics (SPC). - Patients that cannot be treated with topical antiseptic containing Iodopovidone and/or with iodopovidone impregnated gauze according to the contraindication available in the current Summary of Product Characteristics (SPC).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Usual Care alone
Usual Care is defined as the following procedures to apply to the foot ulcer, carried out in the order in which they are listed: Sharp debridement (the debridement will be performed only if non-vital tissue is present), Mild washing of the whole ulcer with physiological solution, Treatment with topical antiseptic containing Iodopovidone, Covering with iodopovidone impregnated gauze while the ulcer is clinically infected (PEDIS = 2) [If, during the study, PEDIS is < 2, the ulcer will be covered with nonadherent paraffin gauze]. Treatment 2 times a week (4 treatment weeks, 8 treatments).
Device:
System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care
System VULNOFAST® plus / VULNOLIGHT®: VULNOFAST® plus sterile solution, in combination with a red light source VULNOLIGHT®. VULNOFAST® plus and VULNOLIGHT® will be used in accordance with their Instructions for Use (IFU) and User Manual. Treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®).

Locations

Country Name City State
Italy U.O.C. Diabetologia e Malattie Metaboliche, Ospedale San Donato Arezzo
Italy Unit Piede Diabetico, SODc Diabetologia e Malattie del Metabolismo, Azienda Ospedaliero-Universitaria Careggi Firenze
Italy Centro di Assistenza Vulnologica, Ospedale Villa Scassi Genova
Italy Unità di Diabetologia, Endocrinologia e Malattie Metaboliche, IRCSS Centro Cardiologico Monzino Milano
Italy U.O. Malattie Endocrine del Ricambio e della Nutrizione, Azienda Ospedaliero-Universitaria Policlinico Giaccone Palermo
Italy Dipartimento di Endocrinologia e Malattie Metaboliche, Centro Piede Diabetico, Ospedale S. Maria della Misericordia Perugia
Italy SOS Diabetologia, Presidio Ospedaliero San Jacopo Pistoia

Sponsors (1)

Lead Sponsor Collaborator
L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the ulcer after 2 weeks of study treatment by evaluation of the following primary endpoint: Proportion of patients who had total bacterial load = 1000 CFU/ml at Visit 5, measured by punch biopsy. Visit 5 is the first visit of 3rd week of treatment.
Secondary The key secondary objective is to evaluate the ulcer after 4 weeks of study treatment by evaluation of the following endpoint: Proportion of patients who had a change of the target ulcer area = 40% from the baseline (Visit 1) to the first follow-up visit (Visit 9) after 4 weeks of study treatment, assessed by MolecuLight i:X medical device. Visit 9 is after 4 weeks of study treatment
See also
  Status Clinical Trial Phase
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Recruiting NCT03964571 - Human and Bacterial Protease Activity as Prognostic Tool of Foot Infections in Diabetic Patients N/A
Completed NCT03230175 - Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01) Phase 2
Completed NCT05616351 - Antibiotic Therapy in Infections of the Diabetic Foot Syndrome
Recruiting NCT05948592 - Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection Phase 2
Recruiting NCT04714411 - Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis
Completed NCT05243810 - EPC Silver Wound Gel (EPC-123) Feasibility Study in the Management of Mildly Infected Diabetic Foot Ulcers N/A
Recruiting NCT05610865 - Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers Phase 1
Recruiting NCT04450693 - Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II) Phase 3
Recruiting NCT05369052 - Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI) Phase 3
Completed NCT02723539 - A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI Phase 1
Completed NCT04440839 - Implementation of Telemedicine for Patient With Lower Extremity Wounds N/A
Withdrawn NCT04289948 - Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes Phase 1/Phase 2
Completed NCT03495349 - Effectiveness and Safety of Antibiotherapy in Diabetic Patients Treated for a Diabetic Foot Infection.
Completed NCT05564728 - Diabetes Footcare Companion App for Patients and Carers
Withdrawn NCT03354806 - Peripheral Analgesia in Painful Diabetic Neuropathy N/A
Completed NCT01590758 - Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers Phase 3
Completed NCT01594762 - Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers Phase 3
Active, not recruiting NCT05174806 - Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients Phase 2
Recruiting NCT04141787 - Ceftriaxone as Home IV for Staph Infections Phase 4